CJC-1295 and ipamorelin have a reason to be paired. The proof needs work.

CJC-1295 acts on the growth hormone-releasing hormone receptor—a receiving point for a signal. Ipamorelin acts on the ghrelin receptor; ghrelin is involved in hunger. Both can signal the pituitary, a small gland in the brain, to release growth hormone. They reach it through different signals.

In an experiment with engineered cells, activating both receptor systems strengthened a signal inside the cells. That gives the idea some footing. It wasn’t a test of this fixed combination in people, let alone a test of better sleep.

The idea has some footing. The pair still needs its own test.

The separate CJC-1295 studies and ipamorelin studies are useful, too. They just don’t add up to a trial of the pair. There’s still a step between explaining why something might work and finding out whether it does.

DAC stands for Drug Affinity Complex. It’s an addition that lets CJC-1295 attach to albumin, a protein in blood, and stay around longer. The familiar human hormone findings come from that long-acting form.

Those extra letters change which study applies.

The FDA’s review treats DAC and non-DAC forms as different active ingredients that aren’t interchangeable. It found no human studies of the non-DAC forms it assessed. A similar name can’t fill that gap.

People in research-use communities report better sleep and recovery with the pair. Those accounts are anecdotal, not clinical evidence. I haven’t found a controlled human trial of this fixed combination in the sources here. That leaves the everyday benefits unproved.

The broader safety review raises concerns about blood sugar and insulin sensitivity—how readily the body responds to insulin. Fluid retention also matters. These are concerns about the drug class, not measured harm rates from a trial of this blend.

Long-term safety is still an open question.

Promise Peptides (mypromise.com) lists a CJC-1295 and ipamorelin blend in its prescription peptide care. A licensed U.S. provider reviews your circumstances and makes the prescribing decision; not everyone qualifies. Care is for people in the United States only, and the compounded medicines are not FDA-approved.

For the regulatory detail, FDA’s page current as of April 22, 2026 lists CJC-1295 as nominated but withdrawn. Ipamorelin acetate is listed there too and remains in the Category 2 safety-concern group under the 503B policy for outsourcing facilities. Withdrawal isn’t clearance.